Citation Impact
Citing Papers
Mucosal healing in inflammatory bowel diseases: a systematic review
2012 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
The gut microbiota and host health: a new clinical frontier
2015 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
2016
ATR-FTIR spectral discrimination between normal and tumorous mouse models of lymphoma and melanoma from serum samples
2017
Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring
2021 StandoutNobel
Advances in antibiotic therapy in the critically ill
2016
Optical coherence tomography angiography
2017 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
2015
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Rheumatoid arthritis
2016 Standout
Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease
2014
Ulcerative Colitis
2011 Standout
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
2009
Complement, a target for therapy in inflammatory and degenerative diseases
2015
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
Foxp2 controls synaptic wiring of corticostriatal circuits and vocal communication by opposing Mef2c
2016 StandoutNobel
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
2020 Standout
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
2010
Guidelines for the management of inflammatory bowel disease in adults
2011
Use of thiopurines in inflammatory bowel disease: Safety issues
2014
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
Crohn's disease
2012 Standout
Synaptic Dysfunction in Neurodevelopmental Disorders Associated with Autism and Intellectual Disabilities
2012
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
2009
Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer
2016 Standout
Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease
2010
Psoriasis
2021 Standout
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
2001 Standout
Epidemiology and risk factors for IBD
2015 Standout
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
2014 Standout
The serotonin system in autism spectrum disorder: From biomarker to animal models
2015
Biological Therapies for Inflammatory Bowel Diseases
2009
Inflammation and Colon Cancer
2010 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
2013
Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?
2010
Ulcerative colitis
2012 Standout
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease
2010
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update
2012
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
Crohn's disease
2016 Standout
Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease
2008
Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?
2015 Standout
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
2017
Infliximab for the treatment of ulcerative colitis
2009
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
2012
Ulcerative colitis
2016 Standout
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
2014
Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy
2010
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Optimizing anti-TNF treatments in inflammatory bowel disease
2013
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Ulcerative colitis
2020 Standout
Anti–tumor necrosis factor-α therapy in uveitis
2015
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
2015
A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
2010
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
2016
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
2018 Standout
Epidemiology and Natural History of Inflammatory Bowel Diseases
2011 Standout
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
2011
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
2010
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Management of Crohn's Disease in Adults
2009 Standout
Immunometabolism: new insights and lessons from antigen-directed cellular immune responses
2020
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011 Standout
Rethinking the INN system for therapeutic antibodies
2016
Hepatosplenic T cell lymphoma in inflammatory bowel disease: Table 1
2008
Therapeutic drug monitoring in patients with inflammatory bowel disease
2014
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
2015
Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
2014
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Detection of Antibodies in Blood Plasma Using Bioluminescent Sensor Proteins and a Smartphone
2016
Atypical Hemolytic Uremic Syndrome: A Meta‐Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens
2017
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
2012
Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications
2018 Standout
Leptomeningeal disease: current diagnostic and therapeutic strategies
2017
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
2019
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
2019 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet
2010
Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases
2017
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
2015
Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies
2018
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy
2015
Parellel inhibition of LH-RH-induced cyclic AMP accumulation and LH and FSH release by LH-RH antagonists in vitro.
1975 StandoutNobel
Works of David Ternant being referenced
A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen
2017
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
2011
Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review
2015
An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab
2006
Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis
2010
Behavior and serotonergic disorders in rats exposed prenatally to valproate: A model for autism
2009
Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients
2008
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis
2011
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
2015
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease
2014
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
2008
Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects
2007
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
2011
Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases
2013
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
2017
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab
2009
Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis
2014
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
2011
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
2015
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis
2017
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
2008
Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer
2014
FcγRIIIa Expression Is Not Increased on Natural Killer Cells Expressing the FcγRIIIa-158V Allotype
2008
Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer
2016